What patents cover an ipratropium inhaler using HFC-152a as the propellant?
Ipratropium inhalers are typically built around a metered-dose inhaler (MDI) platform, and the patent landscape usually splits into (1) drug formulation and particle/excipient choices, (2) device/actuation components, and (3) the propellant system. If your specific interest is “HFC-152a” (1,1-difluoroethane) as the propellant in an ipratropium-containing MDI, you would look for patents that explicitly claim:
- an ipratropium formulation combined with HFC-152a (sometimes with co-solvents and/or water/ethanol),
- a container/valve system suitable for that propellant and fill formulation,
- and dose delivery specs (e.g., actuator output).
To identify the exact patents, you normally search patent databases using combinations of terms such as “ipratropium” + “HFC-152a” + “metered dose inhaler” + “MDI” (and related synonyms like “1,1-difluoroethane”), then filter for active jurisdictions and assignees.
How do you search effectively for “ipratropium inhaler HFC 152a” in patent databases?
A practical search strategy is to combine:
- Drug term: “ipratropium”, sometimes paired with salt forms (for example, “ipratropium bromide”)
- Propellant term: “HFC-152a”, “1,1-difluoroethane”, or “difluoroethane”
- Dosage form/device term: “metered dose inhaler”, “MDI”, “aerosol”, “valve”, “actuator”
- Claim-language filters: look for patents where the propellant is explicitly listed in the independent claims (not only described in the background)
Because many patents describe “fluorocarbon propellants” more broadly (or list multiple propellants), you also want to confirm that the claims cover HFC-152a specifically rather than a generic fluorocarbon range.
When do these patents expire, and does that determine when generic versions can launch?
Patent expiry depends on each family member’s filing and priority dates, plus any patent-term adjustments or extensions in a given country. Even if a propellant-specific patent ends, other patents may still block entry—such as:
- formulation patents (how the drug is dissolved/suspended with specific excipients),
- valve/device patents,
- and new-combination or reformulation patents.
So “propellant patent expiry” is rarely the only gating item for an ipratropium MDI product.
Are there separate patents for the valve, canister, and actuation mechanics versus the propellant?
Yes. For MDIs, patent claim scope often targets:
- the canister/valve chemistry and materials compatible with the propellant,
- actuator geometry and output consistency,
- and the formulation’s interaction with the delivery system.
That means you can find cases where a propellant-formulation claim exists in one set of patents, but device/valve claims exist in another.
What about regulation and replacement of older CFC/HFA propellants—does that affect “HFC-152a” patent relevance?
Propellant choice is strongly linked to regulatory and environmental constraints. If a manufacturer switches propellants (e.g., away from older gases), they may generate new patents for the updated formulation and device compatibility. That can create a new layer of exclusivity around “same drug, different propellant,” even when the clinical active ingredient is unchanged.
Do biosimilar concepts apply here?
For ipratropium MDIs, the relevant pathway is usually generic/locally authorized products and formulation-equivalence concepts, not biologics biosimilars. Patent analysis still matters, but the legal framework and documentation differ from biologic development.
Which jurisdictions matter most for “HFC-152a ipratropium inhaler” patents?
HFC-152a-related patents may be filed in multiple regions, but enforceability and launch timing are driven by where a product will be commercialized (for example, US, EP (EPO), UK, and specific national filings). The “same” patent family can have different effective claim scopes across jurisdictions.
---
Next step (so I can answer with specific patent numbers)
You’ll get a much more accurate answer if you share one detail:
1) Which country/region (US, EP/EU, UK, etc.) you care about, and
2) Whether you mean a brand product (if any) or just “ipratropium bromide MDI” generically.
With that, I can narrow to the likely patent families that explicitly mention HFC-152a and list the relevant publication/application numbers and assignees.